Table 1.
Clinical trials
| No. | Status | Study title | NCT number | Cancer type | Virus |
|---|---|---|---|---|---|
| 1 | Recruiting | UARK 2014-21A Phase II trial of oncolytic virotherapy by systemic administration of Edmonston strain of measles virus | NCT02152775 | Multiple myeloma | MV-MS |
| 2 | Recruiting | MV-NI5 infected mesenchyma I stem cells in treating patients with recurrent ovarian cancer | NCT02068754 | Ovarian cancer | VSV-hIFNbeta-NIS |
| 3 | Recruiting | Trial of intratumoral administration of recombinant vesicular stomatitis virus in patients with refractory solid tumors | NCT02923466 | Malignant solid tumor | VSV-IFNβ-NIS |
| 4 | Recruiting | Modified measles virus (MV-HIS) for children and young adults with recurrent medulloblastoma or recurrent ATRT | NCT2962167 | Medulloblastoma | MV-NIS |
| 5 | Active, not recruiting | VSV-hIFNbeta-NIS in treating patients with relapsed or refractory multiple myeloma, acute myeloid leukemia, or T-cell lymphoma | NCT03017820 | Lymphoma | VSV-hIFNbeta-NlS |
| 6 | Recruiting | Viral therapy in treating patients with recurrent or metastatic squamous cell carcinoma of the head and neck cancer or metastatic breast cancer | NCT01846051 | Breast cancer | MV-NIS |
| 7 | Not yet recruiting | Trial of intravesical measles virotherapy in patients with bladder cancer who are undergoing radical cystectomy | NCT03171453 | Urothelial carcinoma | MV-NIS |
| 8 | Not yet recruiting | V5V-h1Fhlbeta-NIS in treating patients with stage IV or recurrent endometrial cancer | NCT03120624 | Endometrial adenocarcinoma | VSV-hIFNbeta-NIS |
| 9 | Recruiting | Gene therapy and radioactive iodine in treating patients with locally recurrent prostate cancer that did not respond to external-beam radiation therapy | NCT00788307 | Prostate cancer | Ad5-CMV-Hl5 |
| 10 | Recruiting | Trial of measles virotherapy in combination with atezolizumab in patients with metastatic non-small cell lung cancer | NET02515449 | Non-small cell lung cancer | MV-NIS |
| 11 | Active, not recruiting | Recombinant measles virus vaccine therapy and oncolytic virus therapy in treating patients with progressive, recurrent, or refractory ovarian epithelial cancer or primary peritoneal cancer | NCT00408550 | Ovarian cancer | MV-NlS |
| 12 | Recruiting | MV-NIS or investigator’s choice chemotherapy in treating patients with ovarian and fallopian, or peritoneal cancer | NCT02364713 | Ovarian cancer | MV-NIS |
| 13 | Suspended | Vaccine therapy in treating patients with malignant peripheral nerve sheath tumor that is recurrent or cannot be removed by surgery | NCT02700230 | Peripheral nerve sheath tumor | MV-NlS |
| 14 | Recruiting | Vaccine therapy with or without cyclophosphamide in treating patients with recurrent or refractory multiple myeloma | NCT00450814 | Plasma cell myeloma | MV-NIS |
| 15 | Recruiting | Intrapleural measles virus therapy in patients with malignant pleural mesothelioma | NCT01503177 | Mesothelioma | MV-MS |
| 16 | Active, not recruiting | Positron emission tomography imaging studies with NIS reporter | NCT02907073 | Endometrial cancer | MV-NIS |
Note: List of main clinical trial using imaging reporter.
Abbreviations: ATRT, atypical teratoid rhabdoid tumors; NCT, National Clinical Trial; NIS, sodium iodide symporter.